No survival advantage was observed for NDRG1‐low tumours in the HER2+ or TNBC group (Figure 1L,M); however, NDRG1‐low tumours in the ER+ group showed a significantly improved BCSS (Figure 1K). This evidence concerns the gene NDRG1 and neoplasm.